investors & media

There are currently no events to display.

corporate profile

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.. We’re putting our care and expertise to work across a spectrum of disorders by researching cerebral adrenoleukodystrophy, sickle cell disease, transfusion-dependent β-thalassemia and multiple myeloma using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing. bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland.

stock quote

Copyright West LLC. Minimum 15 minutes delayed.

press releases


CAMBRIDGE, Mass. & MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 12, 2019-- bluebird bio, Inc. (Nasdaq: BLUE) and Forty Seven, Inc. (Nasdaq:FTSV) announced today that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven’s novel antibody-based conditioning

Read more

Updated safety and efficacy results from ongoing Phase 1 CRB-402 study of bb21217 in relapsed/refractory multiple myeloma Updated results from ongoing Phase 1/2 (HGB-206) study of LentiGlobin™ gene therapy for patients with sickle cell disease New data from ongoing Phase 3 studies of LentiGlobin™

Read more

- Continued progress towards 2022 vision of four marketed gene and cell therapy products with robust development pipeline - - ZYNTEGLO commercial launch advancing with European Medicines Agency approval of refined commercial manufacturing process - - Ended quarter with $1.41 billion in cash, cash

Read more